Please login to the form below

Not currently logged in
Email:
Password:

BioAlliance announces managerial changes

Dr Gilles Avenard resigns as board member and deputy CEO in charge of R&D, while Dr Pierre Attali becomes CEO

BioAlliance Pharma, a company dedicated to the supportive care and treatment of cancer patients, has announced changes to its management structure.

Dr Gilles Avenard has resigned as board member and deputy CEO in charge of R&D, while Dr Pierre Attali, who has been serving BioAlliance Pharma as chief medical officer for several years, has been appointed as the company's CEO.

Dominique Costantini, CEO of BioAlliance Pharma commented: "I am delighted by Pierre Attali's appointment. His international experience in drug development, notably at Synthelabo, and his hospital practice are major assets for both the company and its commercial partners when preparing the next launches of BioAlliance's products."

4th August 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...
Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...